Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 Oktober 2021 - 10:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
October 28, 2021
(Commission File No. 001-40505)
Ambrx Biopharma Inc.
(Translation of registrant’s name into
English)
Cayman Islands
(Jurisdiction of incorporation or
organization)
10975 Torrey Pines Road
La Jolla, California 92037
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is
submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Earnings Release
On October 28, 2021, Ambrx Biopharma Inc.
issued a press release regarding its financial results as of and
for the six months ended June 30, 2021 and recent business
highlights, which is attached to this Form 6-K as Exhibit 99.1.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereto duly
authorized.
|
|
|
Ambrx Biopharma Inc. |
|
|
By:
|
|
/s/ Feng Tian
|
Name:
|
|
Feng Tian, Ph.D.
|
Title:
|
|
Chief Executive Officer
|
Date: October 28, 2021
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Apr 2022 bis Mai 2022
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mai 2021 bis Mai 2022